IN2012DN01642A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01642A
IN2012DN01642A IN1642DEN2012A IN2012DN01642A IN 2012DN01642 A IN2012DN01642 A IN 2012DN01642A IN 1642DEN2012 A IN1642DEN2012 A IN 1642DEN2012A IN 2012DN01642 A IN2012DN01642 A IN 2012DN01642A
Authority
IN
India
Prior art keywords
compounds
pentoxifylline
derivatives
relates
novel
Prior art date
Application number
Inventor
Roger D Tung
Julie F Liu
Scott L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2012DN01642A publication Critical patent/IN2012DN01642A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
IN1642DEN2012 2009-09-02 2010-09-01 IN2012DN01642A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23933609P 2009-09-02 2009-09-02
PCT/US2010/047574 WO2011028835A1 (en) 2009-09-02 2010-09-01 Substituted xanthine derivatives

Publications (1)

Publication Number Publication Date
IN2012DN01642A true IN2012DN01642A (en) 2015-06-05

Family

ID=43649624

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1642DEN2012 IN2012DN01642A (en) 2009-09-02 2010-09-01

Country Status (8)

Country Link
US (1) US8952016B2 (en)
EP (1) EP2473052A4 (en)
JP (1) JP2013503883A (en)
AU (1) AU2010289551A1 (en)
CA (1) CA2771331A1 (en)
IN (1) IN2012DN01642A (en)
MX (1) MX2012002704A (en)
WO (1) WO2011028835A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265334A2 (en) 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20100159034A1 (en) * 2008-12-15 2010-06-24 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
CA2771331A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031138A2 (en) * 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
WO2012031073A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2013013052A1 (en) * 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330742C2 (en) 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1- (Oxoalkyl) -3-methyl-7-alkylxanthines, process for their preparation and pharmaceuticals containing them
JPS5576876A (en) 1978-12-05 1980-06-10 Grelan Pharmaceut Co Ltd Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne
JPS55122779A (en) 1979-03-13 1980-09-20 Maruko Seiyaku Kk Preparation of theobromine derivative
CS201558B1 (en) 1979-05-14 1980-11-28 Pavol Kovar Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine
JPS567785A (en) 1979-07-02 1981-01-27 Maruko Seiyaku Kk Preparation of theobromine derivative
JPS5610187A (en) 1979-07-05 1981-02-02 Grelan Pharmaceut Co Ltd Separation and purification of 1-(5-oxohexyl)- 3,7-dimethylxanthine
JPS5610188A (en) 1979-07-06 1981-02-02 Dainippon Ink & Chem Inc Xanthine derivative and its preparation
JPS5632477A (en) 1979-08-27 1981-04-01 Nippon Iyakuhin Kaihatsu Kenkyusho:Kk Preparation of 1- 5-oxohexyl -3,7-dimethylxanthine
JPS5677279A (en) 1979-11-28 1981-06-25 Ota Seiyaku Kk Preparation of xanthine derivative
JPS5711981A (en) 1980-06-26 1982-01-21 Sagami Chem Res Center Theobromine derivative and its preparation
JPS5724382A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Trithiane derivative and its preparation
JPS5724385A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Theobromine derivative and its preparation
JPS5724386A (en) 1980-07-17 1982-02-08 Nissan Chem Ind Ltd Preparation of xanthine derivative
JPS5756481A (en) 1980-09-22 1982-04-05 Kawashima Yakuhin Kaihatsu Kk Production of 1-(5-oxohexyl)-3,7-dimethylxanthine
JPS5762278A (en) 1980-10-01 1982-04-15 Sagami Chem Res Center Theobromine derivative and its preparation
JPS5780385A (en) 1980-11-05 1982-05-19 Mitsubishi Petrochem Co Ltd Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine
JPS5785387A (en) 1980-11-14 1982-05-28 Teikoku Chem Ind Corp Ltd Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine
JPS5798284A (en) 1980-12-10 1982-06-18 Kawashima Yakuhin Kaihatsu Kk Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine
JPS57200391A (en) 1981-06-02 1982-12-08 Daito Koeki Kk 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine
JPS5838284A (en) 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd Method for producing 1-(5'-oxohexyl)-3,7-dimethylxanthine
JPS58134092A (en) 1982-02-05 1983-08-10 Sagami Chem Res Center Theobromine derivative
JPS58150594A (en) 1982-03-03 1983-09-07 Daito Koeki Kk Preparation of xanthine derivative
CS237719B1 (en) 1983-05-12 1985-10-16 Jan Jendrichovsky Process for the preparation of dimethyl (5-oxohexyl) xanthines
DE3508097A1 (en) 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt COMBINATION PRODUCT MADE OF XANTHINE DERIVATIVES AND O-ACETYLSALICYL ACID OR THEIR PHARMACOLOGICALLY COMPATIBLE SALTS AND THE USE THEREOF
DE3525801A1 (en) 1985-07-19 1987-01-22 Hoechst Ag TERTIA HYDROXYALKYLXANTHINE, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCT CONTAINING IT AND THEIR USE
DD274334A3 (en) 1985-12-17 1989-12-20 Dresden Arzneimittel PROCESS FOR PREPARING PURE 3,7-DIMETHYL-1- (5-OXOHEXYL) -XANTHINE
IL106861A (en) 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
DE3942872A1 (en) 1989-12-23 1991-06-27 Hoechst Ag METHOD FOR THE ENANTIOSELECTIVE PRESENTATION OF ((OMEGA) -1) -HYDROXYALKYLXANTHINES
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
WO1992007566A2 (en) 1990-11-01 1992-05-14 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
DE69119700T2 (en) 1990-11-07 1996-11-07 Hoechst Roussel Pharma Use of xanthines in the manufacture of medicaments to inhibit the proliferation of human retroviruses
EP0493682A3 (en) 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
EP0490181A1 (en) 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5763446A (en) 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
BR9507200A (en) 1994-03-25 1997-09-16 Isotechnika Inc Improved drug efficacy by deuteration
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2190511A1 (en) 1994-05-16 1995-11-23 J. Peter Klein Asymmetric synthesis of chiral secondary alcohols
AU3539795A (en) 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
DE19544768C1 (en) 1995-11-30 1997-07-10 Rentschler Arzneimittel Use of a combination of pentoxifylline with type I interferons to treat multiple sclerosis
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6316458B1 (en) * 1999-04-30 2001-11-13 Cell Therapeutics, Inc. Method of enhancing insulin action
DE60001623T2 (en) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoyl heteroaryl pyrazole compounds for use as an analgesic / anti-inflammatory agent
WO2003013568A1 (en) 2001-08-02 2003-02-20 Ortho-Mcneil Pharmaceutical, Inc. Cytokine modulation therapy
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2005023193A2 (en) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methods of treating endometriosis
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic Compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
EP2265334A2 (en) * 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8263601B2 (en) * 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
CA2771331A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives

Also Published As

Publication number Publication date
EP2473052A4 (en) 2013-03-20
JP2013503883A (en) 2013-02-04
WO2011028835A1 (en) 2011-03-10
US8952016B2 (en) 2015-02-10
EP2473052A1 (en) 2012-07-11
AU2010289551A1 (en) 2012-03-01
MX2012002704A (en) 2012-03-21
CA2771331A1 (en) 2011-03-10
US20110059995A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
PH12012500278A1 (en) Substituted xanthine derivatives
WO2009108383A3 (en) Substituted xanthine derivatives
IN2012DN01642A (en)
CA2871471C (en) Dna-pk inhibitors
MX2009008253A (en) Kinase inhibitors.
MX2012000709A (en) Pyrrolopyridine inhibitors of kinases.
MX2009009590A (en) Aminopyrimidines useful as inhibitors of protein kinases.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX365294B (en) Dna-pk inhibitors.
MD4820B1 (en) Substituted dihydroisoquinolinone compounds
MX2009010037A (en) Aminopyrimidines useful as kinase inhibitors.
MX2011009796A (en) Inhibitors of pi3 kinase.
UA110197C2 (en) To novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same
MX350761B (en) Isoindolinone inhibitors of phosphatidylinositol 3-kinase.
MX2009009592A (en) Aminopyridines useful as inhibitors of protein kinases.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2009011811A (en) Aminopyrimidines useful as kinase inhibitors.
MX2009000169A (en) Purinone derivatives as hm74a agonists.
MX2012001134A (en) Compositions and methods for inhibition of the jak pathway.
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof
PH12017500089A1 (en) Aldosterone synthase inhibitors
MX2011008645A (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase.
WO2013155465A8 (en) Substituted xanthine derivatives
MX2011012524A (en) Inhibitors of c-met protein kinase.
WO2010107791A3 (en) Pyrazinoisoquinoline compounds